图片名称

Molecular Targeting Mechanisms and Drug Discovery Group

Research Directions and Progress:

1. Novel mechanisms of endoplasmic reticulum (ER) stress regulation and ER stress based therapeutic strategies for cancer. Tumor cells require massive protein synthesis to meet their rapid proliferation demands, and thus exhibit high ER stress activity. We will employ high throughput screening to identify drugs that synergize with ER stress, thereby providing new specific targets and therapeutic strategies for tumor targeted therapy.

2. Development of andrographolide derivatives and the biological mechanisms underlying their actions. To improve the water solubility of andrographolide, we have modified its chemical structure, synthesized 30 derivatives, and systematically validated their effects and activities. We will select derivatives with high activity, improved water solubility, and low toxicity for clinical applications in anti inflammatory, antiviral, and antitumor therapies.

DNA Tumour Virus Group

Our research team deciphers critical virus–host interactions to discover breakthrough therapeutics that eliminate viruses—the root cause of numerous chronic human diseases, including virus-driven cancers. By integrating AI-assisted computational tools, we cost-effectively fast-track the screening and validation of target-specific therapeutic molecules to translate fundamental biological discoveries into first-in-class virus-elimination solutions.

To date, our pipeline has yielded four proprietary target-specific molecules alongside a targeted nano-delivery platform. We aim at dual-commercialization pathway: short-term deployment through innovative targeted medical devices, followed by mid-to-long-term development into high-value pharmaceutical candidates.

图片名称
图片名称

Autoimmune Disease Laboratory

Autoimmune diseases are a group of more than 80 related disorders, and affect 4-10% of the population worldwide. Most autoimmune diseases are chronic and incurable, and urgently need better treatments. Previous studies from our group and others have shown that UBASH3A is associated with seven different autoimmune diseases and inhibits T cell function. Our group has been developing novel UBASH3A-targeted small-molecule compounds to treat autoimmune diseases. First, we completed a large-scale in silico screening of 1.7 million small-molecule compounds and identified 50 candidate UBASH3A-targeted compounds. Next, we performed phenotypic screening and identified several candidate compounds that modulate T cell activation and function. Currently, we are conducting preclinical studies using animal models of autoimmune diseases. This project was supported by a high-level talent award from Taizhou City to Dr. Yan Ge.

In addition, our group has been collaborating with Sarawak Biodiversity Center, Malaysia, to exploit natural products derived from traditional medicinal plants in Sarawak and develop new drugs for autoimmune diseases. This collaborative project has been supported by two fellowships awards from ICGEB and the Chinese Ministry of Science and Technology. 

Biology and Diagnostic Technology Group

Our group focuses on the development of innovative biologics, novel diagnostic reagents, and functional biological raw materials. In the biologics direction, we are currently advancing the development of anti‑fibrosis antibodies. Leveraging the Clonepix2 platform at our offshore laboratory located at the ICGEB headquarters, we are conducting stable cell line development. We have completed laboratory‑scale transient transfection to obtain the target antibodies and are now evaluating antibody expression levels and biological activities. In parallel, we are investigating Nectin‑4 monoclonal antibodies and ADC drugs, as well as expression and purification of recombinant antibodies against avian influenza H5HA, laying the groundwork for subsequent pharmacodynamic evaluation.

In the diagnostic and functional raw materials direction, we have established multi‑system protein expression platforms in both prokaryotic and eukaryotic hosts. Current technological efforts include a bioreactor for anti‑Vibrio antimicrobial peptides, pMHC multimer preparation, multi‑component formulations of chitosan/Callicarpa nudiflora periodontal hydrogels, and target mRNA recognition based on Cas13a complexes. In addition, we are conducting preliminary sample validation for hemoglobin‑based POCT quantum dot‑labeled antibody detection technology and a differential diagnostic kit for thrombocytopenia, accumulating experimental data to prepare for future translational projects.

图片名称
图片名称

RNA Technology and Vaccine Group

We have established an in vitro RNA synthesis platform and are conducting systematic research on pistol ribozymes and mRNA vaccines.

1. Ribozyme research:
(1) As a novel small nucleic acid drug, the ribozyme effectively inhibits key pathogenic genes of high risk HPV. Combined with AI based approaches, we are rapidly developing novel anti cervical cancer agents, supported by a National Natural Science Foundation of China (NSFC) Young Scientist Grant.
(2) After nucleotide modification, the ribozyme not only efficiently targets the KRAS G12V mutation but also significantly enhances anti tumor efficacy; this work has been published in Cell Chem Biol.
(3) We have developed a new method for assessing the capping efficiency of mRNA vaccines using the ribozyme, and have filed a patent application (CN202410330408.9).

2. In vitro RNA synthesis platform:
Based on a novel engineered T7 RNA polymerase, we have established a highly efficient in vitro transcription system for mRNA vaccine production, with a patent application filed (CN202411515414.8) and a paper published in a Chinese core journal. Meanwhile, we also use a chemical synthesizer to prepare DNA and RNA of various lengths.

3. mRNA vaccine development:
Supported by the Jiangsu Provincial Social Development Major Science and Technology Demonstration Project, we have completed the design, preparation, expression, and anti tumor activity testing of neoantigen mRNA vaccines.